Anebulo Pharmaceuticals, Inc. Operating Income Loss

• Anebulo Pharmaceuticals, Inc. showed a decrease of -11.0% in Operating Income Loss from 2024 to 2025.
• This data is from Anebulo Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on September 29, 2025.
• XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 5 years of available data (2021 to 2025), Anebulo Pharmaceuticals, Inc.'s Operating Income Loss has declined by 155.2%.
• Historical annual values: Fiscal year 2025: -$9.22 million | Fiscal year 2024: -$8.31 million | Fiscal year 2023: -$11.78 million | Fiscal year 2022: -$6.83 million | Fiscal year 2021: -$3.61 million.
• Data sourced from SEC EDGAR public filings as of June 22, 2026.

Last verified: June 22, 2026